- Home
- BRNS
BRNS
Barinthus Biotherapeutics plc
as 04-01-2025 3:32pm EST
| Founded: | 2016 | Country: | United Kingdom |
| Employees: | N/A | City: | DIDCOT |
| Market Cap: | N/A | IPO Year: | 2021 |
| Target Price: | $3.00 | AVG Volume (30 days): | 11.5K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 2 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.55 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.79 - $4.16 | Next Earning Date: | 03-20-2025 |
| Revenue: | $14,969,000 | Revenue Growth: | 1766.46% |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Barinthus Biotherapeutics plc News
BRNS Breaking Stock News: Dive into BRNS Ticker-Specific Updates for Smart Investing
GlobeNewswire
13 days ago
Barinthus Bio Reports Full Year 2024 Financial Results and Updates on Corporate Developments
ACCESS Newswire
15 days ago
Q1 Virtual Investor Summit: On-Demand Presentations Now Live
ACCESS Newswire
a month ago
Barinthus Biotherapeutics plc to Present at the Investor Summit Virtual on March 11
Simply Wall St.
2 months ago
US Exchange Insights: 3 Penny Stocks With Over $40M Market Cap
GlobeNewswire
3 months ago
Barinthus Bio Announces Strategic Focus in Immunology and Inflammation (I&I) and Provides a Financial Update
Simply Wall St.
4 months ago
Edesa Biotech And 2 Other Promising US Penny Stocks For Your Radar
GlobeNewswire
4 months ago
Barinthus Bio Promotes SNAP-TI Co-inventor, Geoffrey Lynn, M.D., Ph.D. to Chief Scientific Officer
GlobeNewswire
5 months ago
Barinthus Bio Announces Results From Ongoing Phase 2b Chronic Hepatitis B Trial, Including Achievement of Functional Cure and HBsAb Seroconversion
Compare BRNS vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "BRNS Barinthus Biotherapeutics plc - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.